[Osteogenic potential of three kinds of calcium phosphate ceramics as carriers for recombinant human morphogenetic protein-2 in vivo].
OBJECTIVE
To investigate and compare the osteogenic potential of three kinds of calcium phosphate ceramic as carriers for recombinant human bone morphogenetic protein-2(rhBMP-2) in vivo.


METHODS
BCP ceramics (HA, TCP, HA/TCP) impregnated with rhBMP-2 (experimental groups) and without rhBMP-2(control groups) were implanted into 6 muscles pockets on the dorsum of 3-month-old Wistar rabbits. The rabbits were sacrificed 2, 4 and 8 weeks after implantation and bone induction was estimated by alkaline phosphatase (ALP) activity measurement. The implants were also examined histologically and histomorphometrically by HE staining and computerized graphical analysis.


RESULTS
The ALP activity of implants with rhBMP-2 was higher than that of control groups (P < 0.05), but there was no difference between 2 and 4 weeks in experimental groups. In all experimental groups, the implants exhibited that new bone formation increased with the lapse of time. The amount of new bone formation is more in HA/rhBMP-2 group than in the other two group in the 2nd and 4th weeks, but there was no difference between them (P > 0.05). In the 8th week, the amount of bone formation was most in HA/TCP with rhBMP-2, and was more than that in the 2nd and 4th weeks. Whereas in control groups, there was only fibrous connective tissue.


CONCLUSIONS
HA/TCP is a good carriers of rhBMP-2 and can be used as bone substitutes clinically.
Long
Hou-qing
HQ
Department of Orthopedics, First Affiliated Hospital, Sun Yat-sen University, Guangzhou Guangdong, P.R. China 510080.
Li
Fo-bao
FB
Wang
Ying-jun
YJ
Liao
Wei-ming
WM
Wang
Hui-xin
HX
D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage* / Q000494:pharmacology; D002130:Calcium Phosphates / Q000737:chemistry*; D002516:Ceramics / Q000737:chemistry*; D004337:Drug Carriers; D004343:Drug Implants; D005260:Female; D008297:Male; D008422:Materials Testing; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D016212:Transforming Growth Factor beta
C525718:BMP2 protein, human; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D002130:Calcium Phosphates; D004337:Drug Carriers; D004343:Drug Implants; D016212:Transforming Growth Factor beta; C020243:calcium phosphate